Fresenius

Texnik xulosa

Indikator	Qiymat	Trend

Indikator	Qiymat	Trend

Indikator	Qiymat	Trend

Indikator	S3	S2	S1	P	R1	R2	R3

Yangiliklar

Reuters - 2 kun oldin

Fresenius: mAbxience And Teva Announce Second Strategic Global License Agreement For Biosimilar Oncology Treatment Candidate

BRIEF-Fresenius: mAbxience And Teva Announce Second Strategic Global License Agreement For Biosimilar Oncology Treatment Candidate Oct 3 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE : MABXIENCE AND TEVA ANNOUNCE SECOND STRATEGIC GLOBAL LICENSE AGREEMENT FOR BIOSIMILAR ONCOLOGY TREATMENT CANDIDATE FRESENIUS SE - AGREEMENT COVERS GLOBAL MARKETS, INCLUD

Reuters - 4 kun oldin

FDA Says Identified Fresenius Kabi USA's Recall For Correction Of Ivenix Infusion System Lvp Software As Most Serious Type

BRIEF-FDA Says Identified Fresenius Kabi USA's Recall For Correction Of Ivenix Infusion System Lvp Software As Most Serious Type Oct 1 (Reuters) - FDA: FDA: FRESENIUS KABI USA, LLC, ISSUES CORRECTION FOR IVENIX INFUSION SYSTEM LVP SOFTWARE DUE TO ANOMALIES THAT MAY CAUSE DELAY/UNDERDOSAGE OF THERAPY FDA: IDENTIFIED FRESENIUS KABI USA'S RECALL FOR C

Reuters - 5 kun oldin

Formycon And Fresenius Kabi Receive FDA Approval For Fyb202/ Otulfitm

BRIEF-Formycon And Fresenius Kabi Receive FDA Approval For Fyb202/ Otulfitm Sept 30 (Reuters) - FORMYCON AG FYB.DE : AND FRESENIUS KABI RECEIVE FDA APPROVAL FOR FYB202/ OTULFITM(USTEKINUMAB-AAUZ) TULFITMRECEIVED FDA APPROVAL FOR BOTH SUBCUTANEOUS AND INTRAVENOUS FORMULATIONS, TO TREAT SAME CONDITIONS AS STELARA® APPROVAL REPRESENTS THIRD SUCCESSFU

Reuters - 3 hafta oldin

FDA Says Fresenius Kabi USA Removes Certain Ivenix Large Volume Pump Primary Administration Sets

BRIEF-FDA Says Fresenius Kabi USA Removes Certain Ivenix Large Volume Pump Primary Administration Sets Sept 16 (Reuters) - FDA: FDA: INFUSION PUMP ADMINISTRATION SET RECALL, FRESENIUS KABI USA REMOVES CERTAIN IVENIX LARGE VOLUME PUMP PRIMARY ADMINISTRATION SETS FDA: FDA IDENTIFIED FRESENIUS KABI USA'S CERTAIN IVENIX LARGE VOLUME PUMP PRIMARY ADMINI

Reuters - 3 hafta oldin

Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site

BUZZ-Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Deutsche Bank cuts Roche ROG.S to "sell" from "buy", citing limited catalyst due to a risk of Roche creating a lot of sunk cost for little ultimate return ** J.P.Morgan upgrades Fresenius FREG.DE to "overweight" from "neutral" as it sees earnings compression at the German healthcare group coming to an

Shartlar

Ommabop aktivlar

Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.

Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi

Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.